Background: The aim of this study was to evaluate the ability of Results: Of the 349 eligible patients (267 men and 82 women), 14 (4.0%) had second primary cancers and 26 (7.4%) had distant metastases at initial staging or during mean follow-up of 15 months after treatment. FDG-PET/CT correctly identified second cancers or distant metastases in 39 of these 40 patients; there was one false negative and 23 false positive FDG-PET/CT results. Therefore, FDG-PET/CT had a sensitivity of 97.5%, a specificity of 92.6%, a positive predictive value of 62.9% and a negative predictive value of 99.7% in detecting second primary cancers and distant metastases. Conclusion:Combined FDG-PET/CT is useful as a primary method for detecting second cancers and distant metastases in patients with HNC.

Although the findings did not show 3D EUS to have a significant advantage over conventional EUS for the accurate evaluation of rectal cancer, a numeric advantage may possibly be statistically significant in a further study with larger cases. Furthermore, stereoscopic visualization provided easier and complete understanding of both focal lesions and lymph nodes.

Secretin-stimulated magnetic resonance cholangiopancreatography not only facilitate the depiction of anatomic variations or morphologic changes of the pancreatic duct in the normal and diseased pancreas but also help assessing functional abnormalities of the exocrine pancreas. In this article, we illustrate findings of normal pancreas and various pancreatic diseases on magnetic resonance cholangiopancreatography after secretin stimulation.